TargetBeta
ARAF
A-Raf proto-oncogene, serine/threonine kinase · also A-Raf, ARAF1 · Mitogen-activated protein kinase kinase kinases
2 programs in company-led studies act on ARAF, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tovorafenibrule | Day One Biopharmaceuticals | phase 3 | 83 running | BRAF, RAF1 | ChEMBL |
| belvarafenibrule | Hanmi Pharmaceutical | phase 2 | 64 running | BRAF, RAF1 | ChEMBL |
Conditions their studies are in
- Melanoma, 2 programs
- Neoplasm Metastasis, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026belvarafenib · Hanmi Pharmaceutical · phase 2 · NCT04835805
- May 31, 2027tovorafenib · Day One Biopharmaceuticals · phase 3 · NCT04775485
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.